Tauriga Sciences Inc. Commences the Largest Tauri-Gum Production Run in Company History in Response to Substantially Improved Macro-Industry Outlook
Tauriga Sciences (OTCQB: TAUG) announced an increased production run of its Tauri-Gum™ product line, featuring enhanced Cannabidiol (CBD) and Cannabigerol (CBG) concentrations of 20mg per gum piece. This strategic move, inspired by a favorable macro-industry outlook, is expected to generate over $1,000,000 in retail value. The company is experiencing heightened interest from retail and wholesale sectors and is focusing on boosting its e-commerce segment. Moreover, Tauriga is enhancing production capabilities to meet rising demand while updating packaging to include certifications and compliance features.
- Increased Tauri-Gum™ production run expected to yield over $1,000,000 in retail value.
- Raised CBD and CBG concentrations to 20mg per piece, enhancing product appeal.
- Growing interest from retail and wholesale customers indicates market potential.
- Strengthening e-commerce business segment shows promising customer acquisition.
- Infrastructure enhancements aim to improve production capacity and meet demand.
- None.
The Tauri-Gum™ Product Line has Increased its Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Infusion Concentrations to 20mg per Each Piece of Chewing Gum
NEW YORK, NY, Feb. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as an ongoing Pharmaceutical Development initiative, today announced that it has commenced the largest Tauri-Gum™ production run in Company history, in response to substantially improved macro-industry outlook. Additionally, the Company continues to experience increasingly strong levels of interest – from a broad array of prospective retail & wholesale customers. When completed, this above-referenced production run will yield Tauri-Gum™ product inventory – worth in terms of retail value – well in excess of
There has also been an important formulation modification, applicable to this production run. The Company has made the strategic decision to increase the CBD and CBG infusion concentrations to 20mg per each piece of chewing gum. Accordingly – Mint, Blood Orange, Pomegranate Tauri-Gum™ flavors (20mg CBD / each piece of chewing gum) and Peach-Lemon, Black Currant Tauri-Gum™ flavors (20mg CBG / each piece of chewing gum). The Packaging will also be updated to reflect all of the certifications (i.e. Kosher, Halal) and compliance features (i.e. QR codes, UPCs).
Moving forward, the Company is confident about its growth prospects for the remainder of Calendar Year 2021. The Company’s highest margin E-Commerce business segment continues to show overall strength and there has been an acceleration in online customer acquisition. Lastly, the Company has worked with great diligence to enhance its existing infrastructure and increase its production capacity – to strengthen its ability to meet potential increases in demand.
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant) & (Vitamin C + Zinc “Immune Booster” Flavor: Pear Bellini). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com
Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 18, 2020, the Company announced that it had filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts.
On October 6, 2020, the Company announced that it has been approved to operate as a U.S. Government Vendor (CAGE CODE # 8QXV4).
The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New York.
DISCLAIMER -- Forward-Looking Statements
This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.
Contact:
Tauriga Sciences, Inc.
4 Nancy Court, Suite 4
Wappingers Falls, NY 12590
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Company Instagram: @taurigum
Personal Instagram: @sethsms47
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
Attachment
FAQ
What new concentration levels have been introduced for Tauri-Gum™ by Tauriga Sciences?
What is the estimated retail value of the new Tauri-Gum™ production run?
When was the announcement regarding the Tauri-Gum™ production run made?
What flavors of Tauri-Gum™ have the new 20mg infusion levels?
What company ticker symbol is associated with Tauriga Sciences?
